- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02204163
Study to Assess the Efficacy and Safety of Eutropin in Prader-Willi Syndrome
A Phase III, Multi-center, Randomized, Comparative, Parallel, Open Study to Assess the Efficacy and Safety After Treatment of Eutropin® Inj. Compared to Genotropin® in Infants/Toddlers With Prader-Willi Syndrome
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Asan Medical Center
-
Seoul, Korea, Republic of
- Samsung Medical Center
-
Suwon, Korea, Republic of
- Ajou University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pediatric patients with PWS confirmed by methylation PCR genetic testing
- Prepubertal pediatric patients (Tanner's Pubertal stage I) at screening
- Pediatric patients who have never been treated with hGH prior to screening, or who had been treated with hGH for less than 6 months if they had a treatment history, and whose last administration was made 6 months prior to screening
- Pediatric patients with normal thyroid function at screening (Those with normal function through a hormonal therapy were allowable.)
- Pediatric patients whose parents or LARs signed the informed consent form in writing after receiving the explanation about the purpose, method, effects, etc. of the clinical study, and who also signed the informed consent form in writing if they are capable of reading and understanding writing.
Exclusion Criteria:
Pediatric patients who are accompanied by other causes for growth retardation as follows except for PWS at screening
: Chronic renal failure (including the case in which renal transplantation has been undergone), Silver-Russell syndrome, Turner's syndrome, Seckel syndrome, Down's syndrome, Noonan syndrome, Cushing's syndrome, congenital infections, psychiatric disorders, chronic debilitating diseases, etc.
- Pediatric patients with malignancy or a history of malignancy at screening
- Pediatric patients with severe respiratory disturbance, or sleep apnoea or a history of respiratory infections with an unknown cause at screening. However, those whose condition had been confirmed to be eligible to participate in the clinical study on investigator's judgment were allowed to participae in the study.
- Pediatric patients with impaired fasting glucose, diabetes, and diabetic retinopathy at screening
- Pediatric patients whose epiphyses are closed with a growth rate of ≤1 cm/year at screening
- Pediatric patients who are being administered any drug that may have an effect on the secretion and actions of hGH (estrogen, androgen, anabolic steroids, corticosteroids, GnRH analogs, thyroxine, aromatase inhibitors, etc.) or anticonvulsants and cyclosporin at screening, and have been administered any of them for a long period of time within 6 months prior to screening (However, those who have been administered a thyroxine preparation for ≥4 weeks on a stable dose [allowable in case the investigator determines the dose is stable even though it is changeable based upon the weight of the pediatric patient] were allowed to participate in the clinical study.)
- Pediatric patients who are being administered any drug (e.g. methylphenidate) for treatment of hyperactivity disorders including attention deficit hyperactivity disorder (ADHD) at screening
- Pediatric patients who are hypersensitive to somatropin or any excipient of the investigational product (cresol or glycerol) or who have a relevant history of hypersensitivity
- Pediatric patients who have participated in any other clinical studies after enrolled in this study or who had participated in any other clinical studies within 3 months prior to enrollment in this clinical study
- Pediatric patients in whom this clinical study is considered to be difficult to be conducted for any other reasons on investigator's judgment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Eutropin
Eutropin 0.24mg/kg/week
|
|
Active Comparator: Genotropin
Genotropin 0.24mg/kg/week
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in height SDS (Standard Deviation Score)
Time Frame: baseline and 52 weeks
|
baseline and 52 weeks
|
Change from baseline in Lean body mass (g)
Time Frame: baseline and 52 weeks
|
baseline and 52 weeks
|
Change from baseline in Percent body fat (%)
Time Frame: baseline and 52 weeks
|
baseline and 52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in height velocity (cm/year)
Time Frame: baseline, 16, 28 and 52 weeks
|
baseline, 16, 28 and 52 weeks
|
Change from baseline in head circumference (cm)
Time Frame: baseline, 16, 28 and 52 weeks
|
baseline, 16, 28 and 52 weeks
|
Change from baseline in cognitive development (score) by Bayley Scale
Time Frame: baseline, 28 and 52 weeks
|
baseline, 28 and 52 weeks
|
Change from baseline in motor development (score) by Bayley Scale
Time Frame: baseline, 28 and 52 weeks
|
baseline, 28 and 52 weeks
|
Change from baseline in weight SDS
Time Frame: baseline 16, 28 and 52 weeks
|
baseline 16, 28 and 52 weeks
|
Change from baseline in BMI (kg/m2) (Body Mass Index)
Time Frame: baseline, 16, 28 and 52 weeks
|
baseline, 16, 28 and 52 weeks
|
Change from baseline in Bone age (month)
Time Frame: baseline and 52 weeks
|
baseline and 52 weeks
|
Change from baseline in Bone mineral density (g/cm)
Time Frame: baseline and 52 weeks
|
baseline and 52 weeks
|
Change from baseline in height (cm)
Time Frame: baseline, 16, 28 and 52 weeks
|
baseline, 16, 28 and 52 weeks
|
Change from baseline in height SDS
Time Frame: baseline, 16 and 28 weeks
|
baseline, 16 and 28 weeks
|
Change from baseline in IGF-1 (ng/mL) and IGF-1 SDS
Time Frame: baseline, 28, and 52 weeks
|
baseline, 28, and 52 weeks
|
Change from baseline in IGFBP-3 (ng/mL) and IGFBP-3 SDS
Time Frame: baseline, 28, and 52 weeks
|
baseline, 28, and 52 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Disease
- Congenital Abnormalities
- Overnutrition
- Nutrition Disorders
- Genetic Diseases, Inborn
- Intellectual Disability
- Abnormalities, Multiple
- Chromosome Disorders
- Obesity
- Syndrome
- Prader-Willi Syndrome
Other Study ID Numbers
- LG-HGCL007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prader-Willi Syndrome
-
University Hospital, ToulouseCompletedPrader Willi SyndromeFrance
-
University of FloridaNational Institutes of Health (NIH)Completed
-
Samsung Medical CenterCompletedObesity | Prader Willi Syndrome
-
Duke UniversityCanadian Institutes of Health Research (CIHR); National Institutes of Health... and other collaboratorsCompleted
-
California State University, FullertonUniversity of FloridaUnknownFamily-based Intervention for Youth With Prader-Willi Syndrome: The Active Play at Home Study (APAH)Childhood Obesity | Prader Willi SyndromeUnited States
-
SanionaCompletedConfirmed Genetic Diagnosis of Prader-Willi SyndromeCzechia, Hungary
-
Weill Medical College of Cornell UniversityNational Institutes of Health (NIH); PWSAUSATerminatedPrader-willi SyndromeUnited States
-
Ferring PharmaceuticalsCompletedHyperphagia in Prader-Willi SyndromeUnited States
-
University of FloridaFoundation for Prader-Willi ResearchCompleted
-
ACADIA Pharmaceuticals Inc.RecruitingHyperphagia in Prader-Willi SyndromeUnited States, Canada
Clinical Trials on Genotropin
-
PfizerCompletedSmall for Gestational Age (SGA)
-
Hanmi Pharmaceutical Company LimitedCompletedAdult Growth Hormone DeficiencyHungary
-
PfizerCompletedShort Stature Born Small for Gestational Age (SGA)Japan
-
PfizerCompletedSmall for Gestational Age
-
PfizerCompletedGrowth Hormone Deficiency | Idiopathic Short StatureUnited States
-
University of Erlangen-Nürnberg Medical SchoolCompletedIdiopathic Short StatureGermany
-
PfizerCompletedIdiopathic Short StatureUnited States
-
PfizerCompleted
-
Ludwig-Maximilians - University of MunichPfizerCompletedJuvenile Idiopathic Arthritis | Still Disease, Juvenile-OnsetGermany
-
The University of Texas Medical Branch, GalvestonCompletedCOVID-19 | Fatigue | Cognitive Impairment | Traumatic Brain InjuryUnited States